Sienna Biopharmaceuticals Inc. launched less than two years ago, but with a clinical pipeline of dermatology and aesthetics drugs developed by a team experienced in these two markets, the company has been able to raise $160.75m since early 2016 – including a recent $74.75m initial public offering.
The leadership team had garnered a dozen and a half approvals in these and other treatment areas
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?